1. Home
  2. TIC vs PHVS Comparison

TIC vs PHVS Comparison

Compare TIC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TIC

Acuren Corporation

HOLD

Current Price

$8.92

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$30.30

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIC
PHVS
Founded
1991
2015
Country
United States
Switzerland
Employees
12760
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TIC
PHVS
Price
$8.92
$30.30
Analyst Decision
Buy
Buy
Analyst Count
5
11
Target Price
$11.20
$41.82
AVG Volume (30 Days)
2.6M
351.0K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$44.09
N/A
Revenue Next Year
$4.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.36
$15.51
52 Week High
$14.94
$33.33

Technical Indicators

Market Signals
Indicator
TIC
PHVS
Relative Strength Index (RSI) 50.09 52.99
Support Level $6.55 $24.73
Resistance Level $9.21 $31.14
Average True Range (ATR) 0.49 1.68
MACD -0.09 0.05
Stochastic Oscillator 18.65 41.73

Price Performance

Historical Comparison
TIC
PHVS

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: